122 related articles for article (PubMed ID: 31137981)
1. Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach.
Mali DP; Bhatia NM
Nat Prod Res; 2021 Jan; 35(1):92-98. PubMed ID: 31137981
[TBL] [Abstract][Full Text] [Related]
2. Hetero-Tricyclic Lead Scaffold as Novel PDE5A Inhibitor for Antihypertensive Activity: In Silico Docking Studies.
Mali DP; Bhatia NM
Curr Comput Aided Drug Des; 2019; 15(4):318-333. PubMed ID: 30767749
[TBL] [Abstract][Full Text] [Related]
3. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
4. E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against cardiovascular diseases.
Maryam A; Khalid RR; Siddiqi AR; Ece A
J Biomol Struct Dyn; 2021 Apr; 39(7):2302-2317. PubMed ID: 32299297
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.
Mittal A; Paliwal S; Sharma M; Singh A; Sharma S; Yadav D
Bioorg Med Chem Lett; 2014 Jul; 24(14):3137-41. PubMed ID: 24856068
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potential inhibitors for phosphodiesterase 5A, sodium-potassium pump and beta-adrenergic receptor from
Gaikwad DT; Jadhav NR
J Biomol Struct Dyn; 2021 Mar; 39(5):1754-1765. PubMed ID: 32141398
[TBL] [Abstract][Full Text] [Related]
7. Novel Pyrazolo[4, 3-c]Quinolin-3-One Derivatives as PDE5A Inhibitors.
Shaik A; Agarwal HK; Bhakuni R; Kirubakaran S
Curr Top Med Chem; 2019; 19(4):305-315. PubMed ID: 30747070
[TBL] [Abstract][Full Text] [Related]
8. Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors.
Niinivehmas SP; Virtanen SI; Lehtonen JV; Postila PA; Pentikäinen OT
J Chem Inf Model; 2011 Jun; 51(6):1353-63. PubMed ID: 21591817
[TBL] [Abstract][Full Text] [Related]
9. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
Lather A; Sharma S; Khatkar A
Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
[TBL] [Abstract][Full Text] [Related]
10. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
11. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
12. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
13. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
Al-Nema M; Gaurav A; Akowuah G
Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
[TBL] [Abstract][Full Text] [Related]
14. Identification of selective inhibitors for phosphodiesterase 5A using e-pharmacophore modelling and large-scale virtual screening-based structure guided drug discovery approaches.
Maryam A; Siddiqi AR; Chaitanya Vedithi S; Ece A; Khalid RR
J Biomol Struct Dyn; 2023 Aug; ():1-16. PubMed ID: 37545162
[TBL] [Abstract][Full Text] [Related]
15. Discover natural compounds as potential phosphodiesterase-4B inhibitors via computational approaches.
Li J; Zhou N; Liu W; Li J; Feng Y; Wang X; Wu C; Bao J
J Biomol Struct Dyn; 2016 May; 34(5):1101-12. PubMed ID: 26159554
[TBL] [Abstract][Full Text] [Related]
16. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux.
Subbotina A; Ravna AW; Lysaa RA; Abagyan R; Bugno R; Sager G
J Pharm Pharmacol; 2017 Jun; 69(6):675-683. PubMed ID: 28211580
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potential Inhibitors of PDE5 based on Structure-based Virtual Screening Approaches.
Xu L; Sun L; Su P; Ma T; Yu Y; Liu H; Huang X
Curr Comput Aided Drug Des; 2023; 19(3):234-242. PubMed ID: 36503473
[TBL] [Abstract][Full Text] [Related]
19. Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation.
Tömöri T; Hajdú I; Barna L; Lorincz Z; Cseh S; Dormán G
Mol Divers; 2012 Feb; 16(1):59-72. PubMed ID: 21947759
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
Chen CY
J Biomol Struct Dyn; 2010 Apr; 27(5):627-40. PubMed ID: 20085380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
